Mirvetuximab soravtansine-gynx: Revision history

15 April 2025

• curprev 11:2811:28, 15 April 2025 Parth Vikram Singh talk contribs 42,612 bytes +5,973 No edit summary
• curprev 11:1611:16, 15 April 2025 Parth Vikram Singh talk contribs 36,639 bytes +1,686 No edit summary
• curprev 11:0011:00, 15 April 2025 Parth Vikram Singh talk contribs 34,953 bytes +3 No edit summary
• curprev 10:5710:57, 15 April 2025 Parth Vikram Singh talk contribs 34,950 bytes +937 No edit summary
• curprev 10:5310:53, 15 April 2025 Parth Vikram Singh talk contribs 34,013 bytes −1 No edit summary
• curprev 10:5110:51, 15 April 2025 Parth Vikram Singh talk contribs 34,014 bytes −1 No edit summary
• curprev 10:4810:48, 15 April 2025 Parth Vikram Singh talk contribs 34,015 bytes −24 No edit summary
• curprev 10:3510:35, 15 April 2025 Parth Vikram Singh talk contribs 34,039 bytes +16,170 No edit summary
• curprev 08:2108:21, 15 April 2025 Parth Vikram Singh talk contribs 17,869 bytes +412 No edit summary
• curprev 08:1408:14, 15 April 2025 Parth Vikram Singh talk contribs 17,457 bytes +8,918 No edit summary
• curprev 06:5106:51, 15 April 2025 Parth Vikram Singh talk contribs 8,539 bytes +4,866 No edit summary
• curprev 06:3106:31, 15 April 2025 Parth Vikram Singh talk contribs 3,673 bytes +855 No edit summary
• curprev 02:4502:45, 15 April 2025 Parth Vikram Singh talk contribs 2,818 bytes +240 No edit summary
• curprev 02:2102:21, 15 April 2025 Parth Vikram Singh talk contribs 2,578 bytes +870 No edit summary

14 April 2025

• curprev 17:4017:40, 14 April 2025 Parth Vikram Singh talk contribs 1,708 bytes +664 No edit summary

13 April 2025

• curprev 16:3516:35, 13 April 2025 Parth Vikram Singh talk contribs 1,044 bytes +1,044 Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Mirvetuximab soravtansine-gynx in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Gu..."